KR20160105443A - 뉴레귤린 제제의 처방 - Google Patents

뉴레귤린 제제의 처방 Download PDF

Info

Publication number
KR20160105443A
KR20160105443A KR1020167020428A KR20167020428A KR20160105443A KR 20160105443 A KR20160105443 A KR 20160105443A KR 1020167020428 A KR1020167020428 A KR 1020167020428A KR 20167020428 A KR20167020428 A KR 20167020428A KR 20160105443 A KR20160105443 A KR 20160105443A
Authority
KR
South Korea
Prior art keywords
polypeptide
concentration
buffer
formulation
nrg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167020428A
Other languages
English (en)
Korean (ko)
Inventor
밍동 쪼우
Original Assignee
젠순 (상하이) 사이언스 앤드 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53493186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160105443(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 젠순 (상하이) 사이언스 앤드 테크놀로지 리미티드 filed Critical 젠순 (상하이) 사이언스 앤드 테크놀로지 리미티드
Priority to KR1020227021093A priority Critical patent/KR102522140B1/ko
Publication of KR20160105443A publication Critical patent/KR20160105443A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020167020428A 2014-01-03 2014-12-17 뉴레귤린 제제의 처방 Ceased KR20160105443A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227021093A KR102522140B1 (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410002665.6 2014-01-03
CN201410002665.6A CN104758922A (zh) 2014-01-03 2014-01-03 纽兰格林制剂的配方
PCT/CN2014/094073 WO2015101182A1 (zh) 2014-01-03 2014-12-17 纽兰格林制剂的配方

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021093A Division KR102522140B1 (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방

Publications (1)

Publication Number Publication Date
KR20160105443A true KR20160105443A (ko) 2016-09-06

Family

ID=53493186

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167020428A Ceased KR20160105443A (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방
KR1020237012378A Pending KR20230054749A (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방
KR1020227021093A Active KR102522140B1 (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237012378A Pending KR20230054749A (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방
KR1020227021093A Active KR102522140B1 (ko) 2014-01-03 2014-12-17 뉴레귤린 제제의 처방

Country Status (10)

Country Link
US (3) US10702585B2 (enExample)
EP (2) EP3090756B2 (enExample)
JP (4) JP6703483B2 (enExample)
KR (3) KR20160105443A (enExample)
CN (4) CN110946993A (enExample)
AU (1) AU2014375637A1 (enExample)
BR (1) BR112016015660A2 (enExample)
CA (1) CA2935607A1 (enExample)
RU (1) RU2738158C2 (enExample)
WO (1) WO2015101182A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3363455A1 (en) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
RU2650962C2 (ru) 2012-06-07 2018-04-18 Чилдрен'З Хоспитал Лос Анджелес Способы лечения нейтропении с применением ретиноидных агонистов
CN109276705B (zh) 2012-10-08 2023-10-20 上海泽生科技开发股份有限公司 治疗糖尿病患者心力衰竭的组份和方法
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN113166218B (zh) 2018-04-11 2024-08-13 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) * 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液
WO2021126882A1 (en) * 2019-12-16 2021-06-24 Seagen Inc. High performance liquid chromatography quantification of excipients

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU732027B2 (en) 1997-02-10 2001-04-12 Genentech Inc. Heregulin variants
KR20010031103A (ko) 1997-10-14 2001-04-16 버틀러 그레고리 비. 네우레굴린을 사용하는 치료요법적 방법
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CN1423696A (zh) 2000-02-28 2003-06-11 解码遗传Ehf公司 人类精神分裂症基因
CA2409996C (en) * 2000-05-23 2016-03-01 Cenes Pharmaceuticals, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2002024889A2 (en) 2000-09-12 2002-03-28 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Optimized cardiac contraction through differential phosphorylation of myosin
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
DE10124387A1 (de) * 2001-05-18 2002-11-28 Basf Ag Hydrophob modifizierte Polyethylenimine und Polyvinylamine zur Antiknitterausrüstung von cellulosehaltigen Textilien
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1573045A4 (en) 2002-11-27 2007-02-21 Artesian Therapeutics Inc DETECTION OF GENES RELATED TO HEART FAILURE AND THERAPEUTIC ASSAY
US20050112128A1 (en) 2003-05-21 2005-05-26 Myogen, Inc. And Board Of Regents, The University Of Texas System Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
GB0413005D0 (en) 2004-06-11 2004-07-14 Coletica Ligand
US20080213395A1 (en) 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
DE602006017071D1 (de) * 2005-01-25 2010-11-04 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
EP3363455A1 (en) * 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
EP1876227B2 (en) * 2006-07-07 2020-08-12 The Procter and Gamble Company Detergent Compositions
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
DK2115477T3 (en) 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20110212108A1 (en) 2008-05-09 2011-09-01 The Regents Of The University Of California Neuregulin/erbb signaling and integrin
AU2009292216B2 (en) 2008-07-17 2015-03-05 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
JP2012509908A (ja) * 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
WO2010060265A1 (en) * 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin peptides and their use
EP2440236B1 (en) 2009-06-09 2016-05-04 Zensun (Shanghai) Science and Technology Limited Neuregulin based methods for treating heart failure
ES2748886T3 (es) 2009-06-09 2020-03-18 Zensun Shanghai Science & Tech Co Ltd Métodos basados en Neuregulina para el tratamiento de la insuficiencia cardíaca
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
CA2989896C (en) 2010-07-22 2021-02-09 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
CN102230084B (zh) * 2011-06-14 2013-01-23 东北大学 低品位含砷难浸金矿的包覆生物氧化预处理方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN109276705B (zh) 2012-10-08 2023-10-20 上海泽生科技开发股份有限公司 治疗糖尿病患者心力衰竭的组份和方法
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Also Published As

Publication number Publication date
JP7100083B2 (ja) 2022-07-12
CA2935607A1 (en) 2015-07-09
RU2016131667A3 (enExample) 2018-08-21
JP2017502969A (ja) 2017-01-26
KR102522140B1 (ko) 2023-04-17
WO2015101182A1 (zh) 2015-07-09
JP2020143101A (ja) 2020-09-10
RU2738158C2 (ru) 2020-12-08
EP3090756B2 (en) 2024-09-25
RU2016131667A (ru) 2018-02-08
US20250073306A1 (en) 2025-03-06
EP3090756A1 (en) 2016-11-09
BR112016015660A2 (pt) 2017-10-24
US10702585B2 (en) 2020-07-07
EP3821904B1 (en) 2025-02-05
EP3090756B1 (en) 2020-09-30
JP7479068B2 (ja) 2024-05-08
KR20230054749A (ko) 2023-04-25
CN111012898A (zh) 2020-04-17
KR20220093387A (ko) 2022-07-05
CN104758922A (zh) 2015-07-08
EP3090756A4 (en) 2017-07-19
JP2022130627A (ja) 2022-09-06
US20170007671A1 (en) 2017-01-12
JP6703483B2 (ja) 2020-06-03
EP3821904A1 (en) 2021-05-19
AU2014375637A1 (en) 2016-07-14
JP2024099628A (ja) 2024-07-25
US11969458B2 (en) 2024-04-30
US20210113661A1 (en) 2021-04-22
CN105960248A (zh) 2016-09-21
CN110946993A (zh) 2020-04-03

Similar Documents

Publication Publication Date Title
KR102522140B1 (ko) 뉴레귤린 제제의 처방
JP7531564B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
JP5781931B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
KR101752508B1 (ko) 제8 인자 제형
US9907829B2 (en) Stable MIA/CD-RAP formulation
SI9420048A (en) Pharmaceutical formulations of nerve growth factor
JP2012506387A5 (enExample)
TW201731488A (zh) 重組ｖｗｆ調配物
CN109276705B (zh) 治疗糖尿病患者心力衰竭的组份和方法
KR102852946B1 (ko) 산 스핑고미엘린분해효소 결핍증을 치료하기 위한 약제학적 조성물
WO2017049205A2 (en) Growth hormone formulation
TW202535919A (zh) 類升糖素肽2(glp-2)類似物之調配物及其用途
TW202200194A (zh) Cnp綴合物的乾燥藥物製劑
JP2009149684A (ja) アミリン作動薬ペプチド用製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160726

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191216

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210223

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211228

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210820

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191216

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160808

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220412

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220325

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211228

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210820

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210223

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191216

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160808

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220621